33 Recruiting Multiple Myeloma Phase 1 / Phase 2 Clinical Trials
Active phase 1 / phase 2 studies for multiple myeloma enrolling across the USA. Verify eligibility and contact site coordinators.
All Multiple Myeloma studiesPhase 1 / Phase 2 Studies for Multiple Myeloma
Ixazomib + Pomalidomide + Dexamethasone In MM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
📍 Hackensack University Medical Center — Hackensack, New Jersey
View Study & Checklist ➔COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
📍 Local Institution - 119 — Denver, Colorado
View Study & Checklist ➔Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
📍 GSK Investigational Site — Salvador, Estado de Bahia
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
📍 GSK Investigational Site — Atlanta, Georgia
View Study & Checklist ➔Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
📍 Mayo Clinic Hospital — Phoenix, Arizona
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
📍 University of Colorado — Aurora, Colorado
View Study & Checklist ➔Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Atlanta, Georgia
View Study & Checklist ➔A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham, Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
📍 GSK Investigational Site — Boston, Massachusetts
View Study & Checklist ➔Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
📍 Weill Cornell Medical College — New York, New York
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
📍 GSK Investigational Site — Atlanta, Georgia
View Study & Checklist ➔Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
📍 Yale New Haven Hospital — New Haven, Connecticut
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
📍 238995 — Atlanta, Georgia
View Study & Checklist ➔A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of California San Francisco (UCSF) - Parnassus Heights /ID# 238680 — San Francisco, California
View Study & Checklist ➔A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
📍 Local Institution - 102 — Scottsdale, Arizona
View Study & Checklist ➔Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
📍 Levine Cancer Institute — Charlotte, North Carolina
View Study & Checklist ➔A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
📍 City of Hope National Medical Center /ID# 273132 — Duarte, California
View Study & Checklist ➔ATRA and Carfilzomib in Plasma Cell Myeloma Patients
📍 Houston Methodist Neal Cancer Center — Houston, Texas
View Study & Checklist ➔Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
📍 Winship Cancer Institute of Emory University — Atlanta, Georgia
View Study & Checklist ➔Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
📍 University of Southern California /ID# 272414 — Los Angeles, California
View Study & Checklist ➔Selinexor and Backbone Treatments of Multiple Myeloma Patients
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
📍 Research Site — Duarte, California
View Study & Checklist ➔A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
📍 GSK Investigational Site — Bullhead City, Arizona
View Study & Checklist ➔A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
📍 University of California Los Angeles (UCLA) — Los Angeles, California
View Study & Checklist ➔Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
📍 Sylvester Comprehensive Cancer Center — Miami, Florida
View Study & Checklist ➔A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
📍 UAB Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
📍 Regional Oncology Center — Wilson, North Carolina
View Study & Checklist ➔